Predicting remission of Graves' disease following treatment with antithyroid drugs
Клинический разбор в общей медицине, 2023 Graves' disease (GD) is among the most prevalent organ-specific diseases and is one of the most common causes of hyperthyroidism in regions with normal iodine supply.
Natalya V. Drogashevskaya +5 more
doaj +2 more sources
Clinical characteristics of antithyroid drug-induced aplastic anemia cases over the past 30 years [PDF]
Frontiers in Endocrinology, 2023 ObjectiveThe authors aimed to investigate the clinical characteristics of antithyroid drug-induced aplastic anemia cases over the past 30 years.MethodsThe data of patients with antithyroid drug-induced aplastic anemia were retrieved from PubMed and ...
Ying Cheng +7 more
doaj +2 more sources
Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2022 Purpose To evaluate the characteristics and frequency of remission in pediatric patients with Graves’ disease (GD) treated with antithyroid drug (ATD) and to identify factors that may be associated with relapse.
Tsz Wai Catherine Wong +1 more
doaj +1 more source
The Early Changes in Thyroid-Stimulating Immunoglobulin Bioassay over Anti-Thyroid Drug Treatment Could Predict Prognosis of Graves’ Disease [PDF]
Endocrinology and Metabolism, 2023 Background To determine whether baseline thyroid-stimulating immunoglobulin (TSI) bioassay or its early response upon treatment with an anti-thyroid drug (ATD) can predict prognosis of Graves’ disease (GD) in real-world practice.
Jin Yu +8 more
doaj +1 more source
The treatment of Graves' disease in children and adolescents [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2014 Graves' disease (GD) accounts for 10%-15% of thyroid disorders in children and adolescents. The use of antithyroid drugs as the initial treatment option in GD is well accepted.
Hae Sang Lee, Jin Soon Hwang
doaj +1 more source
Risk of Diabetes in Patients with Long-Standing Graves’ Disease: A Longitudinal Study [PDF]
Endocrinology and Metabolism, 2021 Background The detrimental effects of excessive thyroid hormone on glucose metabolism have been widely investigated. However, the risk of diabetes in patients with long-standing hyperthyroidism, especially according to treatment modality, remains ...
Eyun Song +10 more
doaj +1 more source
Characteristics of Korean Patients with Antithyroid Drug-Induced Agranulocytosis: A Multicenter Study in Korea [PDF]
Endocrinology and Metabolism, 2015 BackgroundAntithyroid drugs (ATDs) can lead to the development of agranulocytosis, which is the most serious adverse effect. Characteristics of ATD-induced agranulocytosis (AIA) have seldom been reported due to the rarity. In this study, we characterized
Hee Kyung Kim +11 more
doaj +1 more source
Antithyroid Drug Treatment in Graves’ Disease [PDF]
Endocrinology and Metabolism, 2021 Graves’ disease is associated with thyrotropin (TSH) receptor stimulating antibody, for which there is no therapeutic agent. This disease is currently treated through inhibition of thyroid hormone synthesis or destruction of the thyroid gland. Recurrence
Jae Hoon Chung
doaj +1 more source
Endocrinology Research and Practice, 2007 Objective: Hyperthyroidism causes secondary osteoporosis. The aims of our study were to asses how frequent osteoporosis is seen in hyperthyroidism, can euthyroidism reverse bone loss in hyperthyroid osteoporotic patients, do anti resorptive agents ...
Eren Gündüz +4 more
doaj +3 more sources
Study of Serum FSH, LH and Prolactin in Female Albino Rats by Experimentally Creating Hypothyroidism
Annals of Abbasi Shaheed Hospital and Karachi Medical & Dental College, 2021 Objective: The current research was draft to contrast the variation in levels of Prolactin (PRL), Luteinizing Hormone (LH) and Follicle stimulating hormone (FSH) in female rodents by experimentally producing hypothyroidism.
Amber ILyas +5 more
doaj +1 more source